AntiCandiTreat: Echinocandins Versus Azoles for Candidemia Treatment
Study Details
Study Description
Brief Summary
Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Echinocandin group Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia |
Drug: Echinocandin treatment
Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
|
| Triazole group Triazole group is the group of patients who received triazoles as first-line therapy for candidemia |
Drug: Triazole treatment
Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.
Candidemia was defined as at least one blood culture positive for Candida.
|
Outcome Measures
Primary Outcome Measures
- Comparison of all cause hospital mortality on day 90 between echinocandins and azoles [Mortality on day 90 after antifungal initiation]
Comparison of all cause hospital mortality on day 90 between echinocandins and azoles
Secondary Outcome Measures
- Comparison of treatment success on day 30 between echinocandins and azoles. [Treatment success on day 30 after antifungal initiation]
Treatment success is defined as a complete response if the following two criteria were full-filled: survival and resolution of all attributable symptoms and signs of disease, and mycological success (documented clearance of pathogen from the blood).
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles
Exclusion Criteria:
-
Patients with neutropenia
-
Patients without antifungal treatment
-
Patients who received antifungal therapy for more than two days before candidemia diagnosis
-
Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
-
Patients who received less than 4 days of antifungal therapy after candidemia diagnosis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospices Civils de Lyon, Hôpital de la Croix-Rousse | Lyon | France | 69004 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CRC_GHN_2019_001